We have investigated whether the extent of residual leukemia at bone marrow harvest can predict subsequent relapse after autologous bone marrow transplantation (BMT). A total of 29 pre-and post-purged marrow samples from 15 patients with high-risk common acute lymphoblastic leukemia were examined. An accurate quantitation of residual disease was achieved by phage library assay using polymerase chain reaction to amplify the third complementarity determining region of the immunoglobulin gene. The estimated rate of diseasefree survival at 3 years was significantly higher for the patients with less than 5% residual disease among total B cells than for those with greater than 5% before purging (87.5% vs 0%, P ‫؍‬ 0.0013). Furthermore, among patients with subsequent relapse, there was a linear correlation between the quantitated residual tumor burden of pre-purged marrow and remission duration after BMT (r 2 ‫؍‬ 0.888). An accurate quantitative assessment of residual disease in the autograft has a high predictive value for subsequent relapse. A serial assay of residual disease would help us to individualize the treatment for each patient after induction or consolidation therapy.
cantly unfavorable prognosis. 2, 3 However, there has been no conclusive indicator that predicts subsequent relapse.
Polymerase chain reaction (PCR) technology has enabled us to monitor the minimal tumor burden in patients with leukemia. [4] [5] [6] We previously examined the residual disease status in the marrow before bone marrow transplantation (BMT) by PCR amplification of the bcr-abl transcripts in patients with ALL. 7 In that qualitative study, however, we could not find any significant correlation between detectable residual leukemia in the pretransplant marrows and clinical results. Therefore, we postulated that an accurate quantitative assay of minimal residual disease may address this issue.
The current report focuses on the clinical data of 15 highrisk patients with common ALL antigen (CALLA)-positive ALL treated by autologous BMT (auto-BMT). In order to measure accurately the leukemia burden, we employed a phage quantitation assay utilizing PCR targeted to the third complementarity determining region of the immunoglobulin gene (CDR3). Using this method we precisely quantitated the extent of residual disease in pre-and post-purged marrows and evaluated the relation between residual disease and subsequent relapse after BMT. The present study has demonstrated that the extent of minimal tumor burden at bone marrow harvest is correlated with the timing of subsequent relapse. Furthermore, it suggests that an accurate quantitation has a high predictive value for relapse after auto-BMT.
Patients and methods

Patients
We conducted a clinical study of auto-BMT with ex vivo purging in patients with CALLA-positive high-risk ALL. Between 1984 and 1989, 17 patients were enrolled in this study. 8 Eight of the 17 patients were transplanted in 1st CR and the other nine were transplanted subsequently. From 1989 to August 1996, 18 patients were enrolled in this study consecutively, all of whom had been transplanted in 1st CR. ALL was charaterized by unique morphologic features according to the French-American-British classification.
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To be eligible for this protocol, immunophenotyped leukemia blasts at diagnosis were required to be positive for CD10 (Ͼ90%), positive for CD19 and/or CD20 and negative for T or myeloid lineage markers. A patient in 1st CR was considered to be at high risk for relapse if one or more of the following factors were present: age more than 15 years old, initial leukocyte count of 20 000 /l at diagnosis, Ph chromosome, delay in achieving CR of more than 6 weeks.
All patients were treated with 3-or 4-week induction therapy with cyclophosphamide (CY) and vincristine, predonisolone (PSL), asparaginase (ASP) and doxorubicin. After achieving complete remission, patients received three courses of consolidation therapy. The consolidation therapy consisted of etoposide, vindesine, mitoxantrone, cytarabine, CY and ASP.
For only one of the 17 patients enrolled in the early phase of the study, samples were taken at bone marrow harvest and assessed for presence of residual leukemia. In 16 of the 18 patients enrolled in the late phase of the study, a set of pre-and post-purged marrow samples were cryopreserved when the autologous marrow was harvested.
A total of 34 pre-and post-purged marrow samples from the 17 patients were available in this study. In two of the 17 patients we failed to amplify the CDR3 sequences of the leukemia cells at diagnosis. In these patients, we performed PCR amplification once again using re-extracted genomic DNA from another diagnostic sample but failed to amplify leukemia-specific CDR3. In one patient (case 1), almost all of the post-purged marrow cells were lost during the thawing procedure. Twenty-nine samples of pre-and post-purged marrow from the 15 patients were investigated in this study. Informed consent was obtained from all patients.
Ex vivo treatment of BM
A cocktail of monoclonal antibodies, NL-1 (IgG2a,CD10), NL-22 (IgM), and HL-47 (IgM) plus rabbit complement was used for purging as previously described. [8] [9] [10] Under sterile conditions, mononuclear cells were separated by density gradient. After obtaining a final concentration of 2 ϫ 10 7 cells/ml, the cells were incubated first with monoclonal antibodies at 4°C for 30 min, and subsequently with the same volume of rabbit complement (Pel Freez, Rogers, AZ, USA) at 37°C for 1 h. After completion of this purging procedure, cells were washed twice in cold medium with deoxyribonuclease (DNAse from bovine pancreas, Sigma, St Louis, MO, USA) suspended in 100 ml of RPMI 1640 (Gibco, Gaithersburg, MD, USA) with 10% DMSO and 10% micropore-filtered autologous serum, and frozen at Ϫ80°C. DNAse was added to a final concentration of 10 IU/ml to minimise cell clumping. Except in one case, 1 ϫ 10 7 cells were separated from the pre-and post-purged autograft to prepare for the detection of residual disease and frozen under the same conditions as were the infused marrows.
Preparative regimen
Five of the 15 patients were treated with conventional chemotherapy as maintenance during the period from marrow harvest to BMT. All of the 15 patients received 60 mg/kg/day cyclophosphamide once daily i.v for 2 consecutive days (total 120 mg/kg) and cytosine arabinoside 2 g/m 2 twice daily i.v for 2 consecutive days (total 8 g/m 2 ) followed by fractionated total body irradiation (4 ϫ 3.0 Gy fractions on days Ϫ2, Ϫ1, total 12 Gy) as a preparative regimen.
DNA extraction and PCR amplification of the CDR3
Genomic DNA was isolated from the frozen mononuclear cells or from the Wright-Giemsa-stained smears on coverslips as described. 11, 12 All frozen marrow samples were refractionated on a Ficoll-Hypaque gradient to collect living cells. PCR amplification of the CDR3 was performed using V H sense and J H antisense primers with an annealing step at 55°C for 1 min, an elongation step at 70°C for 1 min, and denaturation at 95°C for 1 min for a total of 35 cycles as described. 11, 12 Precautions against cross contamination of amplified material were taken according to the method reported by Kwok et al. 13 Furthermore, DNA preparation, PCR amplification, and subcloning of the samples pre-and post-purging were performed at different times in different places using different reagents before processing the diagnostic marrow specimen in order to avoid contamination.
Subcloning and sequencing of CDR3 from diagnostic marrow samples and generation of allele-specific probes
Subcloning and sequencing of the CDR3 were performed as described. 11, 12 More than 20 CDR3-containing plaques from marrows at diagnosis were sequenced to determine the leukemia-specific CDR3 sequences in each patient using the dideoxy method, and 20-mer leukemia-specific oligonucleotide probes were generated for the phage quantitative assay. These oligonucleotide probes were constructed from the DJ H junction of leukemia-specific CDR sequences, since this region is relatively stable during clonal evolution. 14 
Southern blot analysis of residual leukemia cells in the pre-and post-purged marrow
The presence of residual disease was evaluated by amplification of CDR3 PCR and hybridization by Southern blotting with each patient's leukemia-specific probes as described. 15 The limit of detection for residual disease with this method was one malignant cell in 10 4 -10 5 nucleated cells (data not shown).
Quantitation of residual leukemia cells in the pre-and post-purged autografts
A phage quantitation assay was performed as described. 12, 15 Amplified CDR3-DNA was ligated into a M13mp19 phage vector. One set of filters with transformants was hybridized with 32 P-labeled J constant (Jc) probes and leukemia-specific probes as described. 11, 12 The frequency of residual leukemia cells among B cells was calculated as follows number of plaques positive for leukemia-specific probes number of plaques positive for Jc probes ϫ 100.
The specificity of each leukemia-derived probe was confirmed by hybridization to a filter containing PCR-amplified material from a diagnostic specimen (positive control) and from normal lymphocytes (negative control). 15 The reliability and reproducibility of the quantitation assay used in this study was confirmed by dilution assays as described. 16 These dilution experiments had demonstrated that the V H DJ H joinings of both the normal B cells and the leukemia cells could be relevantly amplified, whereas at dilutions from 10 Ϫ2 to 10 Ϫ4 the calculated frequency of the residual leukemia was slightly (by two-or three-fold) overestimated due to underestimation of the number of normal B cells. 16 
Follow-up of the patient after autologous BMT
In all patients, peripheral complete blood cell counts and segmentation were checked monthly for the 1st year of BMT, then every 2 months up to the 3rd year. From 3 years after BMT the clinical data of each patient were checked two or three times a year.
Statistical analysis
When calculating disease-free survival (DFS), both relapse and death in complete remission were counted as adverse events. Survival curves were estimated using the method of Kaplan and Meier. Differences between survival curves were tested for significance using the log-rank test.
The relative risk of relapse associated with each variable was calculated by determining the relative hazards rate, using the Cox regression-derived model coefficients. The following variables were included in the analysis: (1) residual disease coded as either percentage of leukemic cells in the B cell population, or a variable used to group the percent residual disease into the two categories (у5% vs Ͻ5% in the pre-purged marrow, у0.5% vs Ͻ0.5% in the post-purged marrow); (2) WBC count coding as a variable for у vs less than 30 ϫ 10 9 /l, respectively; (3) age coded as a variable for у vs less than 30 years; (4) sex; and (5) time to achieve CR coded as a variable for у vs less than 6 weeks; (6) karyotype coded as Ph chromosome abnormality; (7) log kill purging efficacy as a variable for у vs less than 1.0; (8) maintenance therapy; (9) lymphoblast by morphological analysis coded as у vs less than 1.0% among nucleated cells. Univariate Cox regression models were used to explore prognostic variables associated with DFS after transplantation. Time was defined to date of analysis (1 March 1998).
Fisher's exact probability test was used to assess the association between covariate and residual disease in the pre-purged marrow. Linear regression analysis was used to assess the relationships between remission duration after BMT and frequency of residual leukemia in the pre-purged marrow among patients with subsequent relapse. Log transformation of remission duration resulted in a more linear distribution and was used in the analysis. Table 1 summarizes the clinical profile of the 15 patients. Six were females and nine males. The median age was 29 years. Six patients had Ph chromosome abnormalities at diagnosis. The WBC count at diagnosis ranged from 300/l to 270 100/l (median 13 300/l). Autografts of all patients were harvested after the completion of consolidation therapy in first remission. Remission was defined as Ͻ5% blast cells in the marrow based on morphological criteria. In each patient, bone marrow was harvested under general anesthesia to yield a minimum of 3 ϫ 10 8 nucleated cells/kg. The median time to achieve CR was 30 days (20 to 111 days), and interval from diagnosis to marrow harvests ranged from 109 to 512 days. The median duration from marrow harvest to BMT was 32 days and ranged from 16 to 92 days.
Results
Patient characteristics
Seventeen leukemia-specific probes were generated from the diagnostic marrows of the 15 patients (Figure 1 ).
Detectable residual disease in autografts
Southern blot analysis and phage assay were used to evaluate residual disease in the 29 pre-and post-purged samples. Table 2 shows the frequency of detectable residual leukemia cells and clinical outcome. In four samples of two patients (cases 3 and 5), residual leukemia was not detected in either the pre-or post-purged marrow samples by Southern blot analysis or on screening a median number of 10 000 CDR3 clones. In the pre-purged marrow samples, residual leukemia was detected in 13 patients by Southern blot analysis and the calculated frequency of residual leukemia cells among total B cells ranged from 1.4% to 83.5% (median 8.1%). However, by morphological analysis, the extent of residual leukemia was evaluated at between 0.0% and 3.2% among nucleated cells.
After ex vivo marrow purging, the residual disease burden was decreased to between 0.09% and 34.6% (median 0.4%), while all of the 12 samples were positive for Southern blot analysis. The log kill efficacy of this purging method varied from a low of 0.29 to a high of 2.28 (median 1.05).
Relationship between residual leukemia and clinical outcome
Seven of the 15 patients relapsed after auto-BMT, and one patient died of interstitial pneumonia in remission 5 months after BMT. Seven patients are alive without disease recurrence. Median follow-up time for patients in continuous remission without relapse is 64 (range, 36 to 172) months.
Among the patients without disease recurrence, the estimated residual disease before purging ranged from less than 0.01% to 3.2%. In contrast, the residual disease burden in the patients who relapsed after BMT ranged from 8.1% to 83.5%. Figure 2 shows the amount of CDR3-PCRdetectable residual leukemia in the autografts. In terms of the pre-purged marrows, setting the cut-off value at 5% makes it possible to identify all the patients who relapsed after BMT. The estimated rate of DFS at 3 years was significantly higher for patients with less than 5% of residual disease than for those with greater than 5% in the pretransplant marrow (87.5% vs 0%, P ϭ 0.0013) (Figure 3 ). Similarly, the 3-year DFS rate was significantly higher for patients with less than 0.5% than for those with greater than 0.5% in the purged marrow (66.6% vs 0%, P ϭ 0.0059). Table 3 lists univariate Cox regression results for DFS after transplantation. Residual disease burden in the pre-and post-purged marrow, age at diagnosis, and time to achieve CR, showed significantly elevated relative risks for relapse. Percentage of lymphoblasts by morphological analysis, WBC counts at diagnosis, sex, Ph chromosome abnormality, log kill purging efficacy and maintenance therapy were not significantly associated with DFS. By comparison, no covariates correlated with residual disease in the pre-purged marrow (Table 4) . When the relation between residual disease status and remission duration among patients with subsequent relapse was examined, residual leukemia burden of the pre-purged marrow was linearly correlated with remission duration after auto-BMT (r 2 ϭ 0.888, P ϭ 0.0015) (Figure 4 ). On the other hand, there was no significant linearity between residual disease status of the post-purged marrow and remission duration (r 2 ϭ 0.501, P ϭ 0.075).
Discussion
We made an accurate quantitation of residual tumor burden of pre-and post-purged marrow. We found that residual disease in pre-and post-purged marrow, but not purging efficacy, was significantly associated with subsequent relapse after auto-BMT. Furthermore, we could retrospectively predict the timing of subsequent relapse, since there was a linear correlation between estimated tumor burden of the pre-purged marrow and remission duration after BMT. These findings suggest that the primary predictor of subsequent relapse was residual tumor burden in the prepurged marrow, and an autograft should be harvested only when in vivo residual disease is reduced sufficiently (to less than 5% among B cells in the present study). Theoretically, two factors contribute to relapse after auto-BMT: (1) insufficient ex vivo purging by chemical, immunological or biological elements; and (2) insufficient in vivo purging by the preparative regimen. 17 Uckun et al 18, 19 demonstrated that in vivo leukemia burden before BMT rather than reinfused residual leukemia cells was associated with relapse after auto-BMT. They, like us, used a quantitative assay, which combines fluorescence-activated multiparameter flow cytometry and cell sorting with leukemic progenitor cell colony assay. They found that residual leukemia burden in pre-purged marrow was significantly associated with relapse after BMT, and there was a significant inverse relation between the estimated extent of residual disease in the pre-purged autografts and remission duration after BMT. These findings are similar to ours. Furthermore, Southern blot analysis in the present study failed to predict relapse. Taken together, these observations suggest that an accurate quantitation rather than a qualitative assay may help to predict clinical outcome. 
Figure 4
Correlation between residual disease in the pre-purged marrow and remission duration after BMT among patients who had relapsed.
Table 4
Relation between the residual leukemia in the pre-purged marrow and other covariates Wasserman et al 6 reported that residual disease at the end of induction therapy was a significant predictor for relapse during therapy but not a predictor for off-treatment relapse in childhood ALL patients, using quantitative methods. Ito et al 16 reported that residual disease burden at the end of chemotherapy was not a predictor for subsequent relapse in patients with B-lineage ALL. They concluded that absence of PCR-detectable residual disease is necessary but not sufficient to achieve a cure when the patient is treated with chemotherapy alone. In our study, the quantitative assay of residual disease before autologous transplantation had good predictive value for subsequent relapse. From these results, we can suggest that the quantitative assay has predictive value especially in cases of bone marrow transplantation. High-dose conditioning regimens should play a significant role in effecting continuation of complete remission after BMT.
Brisco et al 20 reported that early quantitation of leukemic cells after induction therapy was closely related to the probability of relapse. In that study, patients were classified into four groups by extended MRD burden, patients with undetectable residual disease cells, and those with a very low (Ͻ2 ϫ 10 Ϫ5 cells), intermediate (2 ϫ 10 Ϫ5 to 1 ϫ 10 Ϫ3 cells) and high (Ͼ1 ϫ 10 Ϫ3 cells) level of residual disease. There was a remarkable relation between the extent of residual disease and outcome, with a value of more than 1 ϫ 10 Ϫ3 strongly predicting relapse and a value below 2 ϫ 10 Ϫ5 strongly predicting sustained remission. The authors also mentioned that a more intensified induction/ consolidation therapy would salvage patients with relatively low MRD. Although they did not discuss the relation between MRD and time of relapse, almost all of the patients with high MRD seemed to relapse during therapy. Early quantitation of MRD would be valuable for predicting early relapse and advantageous for salvaging patients with early intensive treatment including marrow transplantation.
In this small number of patients, DFS rate was extremely high as compared with patients given chemotherapy alone. In the Japan adult leukemia study group ALL 87 study, the 6-year DFS rate was 24.5% in 116 evaluable patients. 21 As mentioned above, high-dose conditioning regimens may play a special role in the treatment of ALL. However, in some prospective trials, autologous BMT seems no more effective than chemotherapy. In almost all studies, complete remission has been defined on morphological criteria. Generally the frequency of lymphoblasts evaluated by morphological analysis is a reliable predictor of clinical outcome following therapy. However, in some cases, it is difficult to distinguish residual leukemia cells from normal lymphocytes morphologically. In our study, the percentage of lymphoblasts determined by morphological analysis was not associated with residual disease quantitated by molecular analysis. The same finding was noted by Wasserman 6 and Ito. 16 We presume that autologous BMT may be effective for patients with intermediate or relatively low levels of residual disease. For patients with a high residual tumor burden after consolidation therapy, it may be better to chose allogeneic BMT using an unrelated donor or other immunotherapy. A larger study and serial assay of MRD would help us to determine the most suitable therapy for each patient after induction or consolidation therapy.
It is still unclear whether purging helps to prevent relapse after BMT. Gribben et al 22 performed clonogenic assays of the residual lymphoma cells in harvested marrow samples by PCR amplification of the bcl-2/IgH hybrid gene. In that study, all of the 114 pre-purged marrow samples had detectable residual disease, and 57 samples of the post-purged marrows were negative by PCR assay. They demonstrated that DFS after auto-BMT was strongly associated with the absence of detectable lymphoma cells in the post-purged marrow. They used a qualitative assay and did not assess the residual lymphoma burden. Several trials [23] [24] [25] failed to prove that marrow purging influences the ultimate clinical outcome of BMT.
We could not find any relation between purging efficacy and clinical outcome: inadequacy of ex vivo purging in the present study, demonstrated as log 1-2, may account for this. More efficient methods such as immunomagnetic bead selection may be preferable. The clinical impact of ex vivo purging should be further investigated and accurate quantitation of residual disease may be useful in the evaluation of purging.
We have noted the possibility of obtaining false positive or negative results by PCR. Amplification of the DNA released by the lysis procedure may result in false positives and may lead to underestimation of purging efficacy.
To eliminate the DNA released, we washed all of the post-purged marrows in cold medium with DNAse. 22 Therefore, any underestimation of purging efficacy by contamination of the released DNA would be negligible.
In patients with ALL, clonal evolution in the leukemic population may contribute to failure to detect residual disease. 14, 26 Wasserman et al 14 compared the CDR3 sequences in 12 patients with B-lineage ALL at diagnosis and relapse. In that study, six of the seven patients in whom relapse occurred within 36 months had the same CDR3 sequences present at diagnosis and relapse, in contrast, four of the five patients who relapsed more than 72 months after diagnosis had new CDR3 sequences. They suggested that instability of the CDR3 sequences increased as a function of time. In the present study, it is very unlikely that generation of new CDR3 sequences occurred in the short term, since all of the autografts were harvested within 18 months from diagnosis. Furthermore, we compared the CDR3 sequences at diagnosis and relapse in six patients. Sequencing of the CDR3 with an average of 30 clones in each patient revealed all six patients to have the same CDR3 sequence at diagnosis and relapse (data not shown).
In conclusion, an accurate quantitative assessment of residual disease in autograft material has a high predictive value for relapse after auto-BMT. A larger serial study might reveal a strategy for individualizing treatment in ALL.
